Louis M. Weiner, MD, was named the permanent director of the Lombardi Comprehensive Cancer Center at Georgetown University in October 2007. An internationally recognized medical oncologist specializing in the treatment in gastrointestinal cancers, Dr. Weiner is also an accomplished researcher developing novel immunotherapy treatments in his laboratory.
Dr. Weiner is known for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies ─ laboratory-crafted proteins designed to recognize specific cancer cells. His laboratory designs and produces new antibody-based proteins with the aim of improving their tumor-targeting and immune-stimulating properties. This research has led to the surprising and clinically important observation that tumor targeting is impaired if the antibodies attach too tightly to their tumor targets. Dr. Weiner has also developed, and has clinically tested, “bispecific” antibodies and related antibody-based proteins designed not only to recognize and bind to cancer cells but also to stimulate immune-system cells to attack the targeted cancer cells.
As Director of the Lombardi Comprehensive Cancer Center, Chair of the Department of Oncology, Associate Vice President of Georgetown University Medical Center, and Clinical Director of Cancer Services at Georgetown University Hospital, Dr. Weiner is responsible for the operation and development of the cancer center, including its educational, research and clinical missions. In his role as Clinical Director of Cancer Services at Georgetown University Hospital, Dr. Weiner also leads the clinical operation of the Medical Oncology group.
Board certified in internal medicine and medical oncology by the American Board of Internal Medicine, Dr. Weiner has published more than 150 scientific papers and lectures extensively on targeted therapies for cancer. He served as Fox Chase Cancer Center’s principal investigator for the Eastern Cooperative Oncology Group (ECOG) from 1994 until 2002, a major national study group working to improve cancer treatment through clinical trials. Dr. Weiner is also chair of the Immunology Task Force of the American Association of Cancer Research as well as course director for the annual AACR/ASCO Clinical Methods Workshop. He serves on the steering committee of the NCI Translational Research Working Group and on the NCI’s RAID Oversight Committee. He is a standing member of the Cancer Immunopathology and Immunotherapy Study Section of the National Institutes of Health.
Active in many professional organizations, Dr. Weiner is on several journal editorial boards, including Cancer Research and Clinical Cancer Research, and also reviews manuscripts for numerous peer-reviewed medical journals. He has received research awards from the American Cancer Society-Southeast Region, Janssen Pharmaceutical Research Foundation, the Israel Cancer Research Fund, and has received career development awards from the American Cancer Society and National Cancer Institute.